Acne affects most adolescents and young adults with varying severity and presentation. For early or localized forms, the first-line treatment is usually local. The available treatments often lead to local irritation, particularly during the first few weeks of use. This is why creams containing exfoliating agents have long been used in acne, as they are considered to allow a faster disappearance of superficial lesions. The objective of this 6-month double-blind study is to demonstrate in 100 acneic patients the interest of an anti-acne face cream as an adjunct to and in addition to a 5% benzoyl peroxide gel.
The study is conducted in accordance with the protocol and the legislative and regulatory provisions in force (after obtaining authorization of the French health authorities and the favorable opinion of the ethics committee). Regarding the statistical analysis, two different analysis are performed: * Descriptive analysis: quantitative variables are described by the mean and standard deviation and qualitative variables by the raw number of each modality and the corresponding percentage. * Comparative analysis: for quantitative variables, inter-group comparisons are made by a Student's T-test or a non parametric Mann-Whitney test if necessary. For qualitative variables, comparisons are made using a Chi-square test, if the expected number of participants is less than 5, Fischer's exact test on a 4-box contingency tables is used. A significant level of p \<0.05 is considered as significant. A double-data entry is carried out then a comparison of the two databases is performed. Finally internal and external consistency tests are planned. Missing data are described and possibly analyzed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
100
Group A: Eclaran 5% every evening and formula 609567 49 every morning, for 3 months. Then the group is divided: Group A1/ formula 609613 37 and Group A2/ formula 609567 49 every morning, for the next 3 months
Group B: Eclaran 5% every other night and 609613 37 every morning, for 3 months. Then the group is divided: Group B1/ 609613 37 and Group B2/ formula 609567 49 every morning, for the next 3 months
change in the composite score
the investigator evaluates i) the skin sensitivity (erythema, desquamation) and ii) the global tolerance on a 4-point scale (i) from Absent to Important and ii) from Nil to Excellent)
Time frame: from baseline to month 6
change in the lesion count
counting of non-inflammatory (open and closed comedones) and inflammatory (papules, pustules) lesions
Time frame: from baseline to month 6
change in the evaluation of skin sensitivity by the patient
evaluation of the skin sensitivity (pruritus, tingling sensation, burning sensation) on a 4-point scale (from Absent to Important)
Time frame: from baseline to month 6
change in the evaluation of global tolerance by the patient
evaluation on a 4-point scale (from Nil to Excellent)
Time frame: from baseline to month 6
change in the evaluation of the efficacy by the investigator and patient
evaluation on a 4-point scale (from Nil to Excellent)
Time frame: from baseline to month 6
change in the evaluation of the global efficacy by the investigator
evaluation on a 6-point scale (from No lesion to Very severe)
Time frame: from baseline to month 6
change in the quality of life
evaluation of the quality of life of patients with the Cardiff Acne Disability Index (CADI) score
Time frame: from baseline to month 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.